Traversing New Terrains in CLL: The Emerging Role of BTK Inhibitors in the Treatment Landscape 

CEC Oncology
August 20, 2020

CEC Oncology is pleased to present a NCPD-accredited webinar at ONS Bridge 2020: Traversing New Terrains in CLL: The Emerging Role of BTK Inhibitors in the Treatment Landscape.  

Our faculty panel, consisting of Amy Goodrich, RN, MSN, CRNP-AC; Barbara Rogers, CRNP, MN, AOCN, ANP-BC; and John Allan, MD, will review the rationale for targeting the B-cell receptor (BCR) pathway in CLL and its role in tumor proliferation. There will also be discussion regarding the latest safety and efficacy data for BTK inhibitors in CLL based on line of therapy, cytogenetics, and other patient-/disease-specific factors, latest guidelines, as well as identification of patients that would derive benefit from BTK inhibitor therapy. Participants will also gain knowledge about the differences between available BTK inhibitors and how to quickly recognize and appropriately manage adverse events that may arise with therapy. The final portion of the presentation will be interactive and focus on applying the latest evidence into clinical practice by discussing CLL/SLL patient cases and the various challenges faced by clinicians managing patients with BTK inhibitors. There will also be discussion on how BTK inhibitor can be of potential benefit for patients at risk or who contract COVID-19. 

Please join us on Thursday, September 17^th at 9:00 AM EST to receive 1.0 contact hour of NCPD and GrubHub credit for participating and completing the evaluation!